Older Hemophilia Patients have Lower Rates of Multiple Medication Use than Their Peers, Study Reports
Older patients with hemophilia have lower rates of polypharmacy, or use of multiple medications, and of drug-drug interactions than…
Articles by José Lopes, PhD
New Gene Therapy Approach Led to Sustained Benefits in Mouse Model of Hemophilia A, Study Reports
A gene therapy approach using a so-called antibody-drug conjugate (ADC) conditioning regimen led to safe and sustained production of factor…
Hemlibra Use in Severe Hemophilia A Could Save $3 Billion Over 20 Years, Study Estimates
Using Hemlibra (emicizumab) as prophylaxis lowers treatment costs considerably for people with hemophilia A compared to preventative factor (FVIII)…
Cyklokapron Lessens Blood Loss, Joint Pain in Hemophilia A Patients Needing Hip or Knee Surgery, Study Reports
Hemophilia A patients undergoing total hip or knee replacement/reconstruction surgeries have lesser blood loss and require a lower transfusion…
Fewer Bleeding Events, Infusions with Extended Half‐Life Products for Hemophilia, European Survey Finds
Switching to extended half-life (EHL) products has provided a reduction in the number of infusions and fewer bleeding events…
Pfizer’s Expansion in North Carolina May Help Advance Manufacturing of Hemophilia Gene Therapies
Pfizer will invest an additional $500 million into the construction of its new manufacturing facility in Sanford, North Carolina,…
Hemophilia B Affects Relationships of Adults and Children, U.S. Study Finds
Mild to moderate hemophilia B affects the relationships of adult patients, children with the disease and their caregivers in…
Hemophilia Limits Quality of Sex Life, Two Studies Reveal
Although most patients report that discussing their sexual health with their doctors is helpful, hemophilia significantly affects the quality…
Hemophilia Patients at Greater Risk for Hypertension, Swedish Study Finds
The prevalence of hypertension is higher in patients with hemophilia than in the general population, according to a nationwide…
Hemlibra May Surpass Bypassing Agents in AHA, Study Says
An 87-year old woman with acquired hemophilia A (AHA) showed no adverse events or major bleeding events after starting…